Tuesday, January 26, 2021

NRGene Raises $30M On Tel-Aviv Stock Exchange

San Diego-based biotech investor NRGene, which says it is using artificial intelligence for genomics in the agricultural and livestock industry, says it has completed an initial public offering (IPO) on the Tel-Aviv Stock Exchange, and raised approximately $30M. The company says it is now trading as NRGN on the Tel Aviv Stock Exchange. The company's CEO and co-founder is Dr. Gil Ronen. The company says its technology has been used in more than 250 projects globally, including by such companies as Bayer and Syngenta.